Emergent BioSolutions Inc. Common Stock (NY:EBS)

6.330 -0.040 (-0.63%)

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Emergent BioSolutions Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08

March 20, 2025

From Emergent BioSolutions

Via GlobeNewswire

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

March 20, 2025

Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada

From Emergent BioSolutions

Via GlobeNewswire

Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International

March 19, 2025

From Emergent BioSolutions

Via GlobeNewswire

Where Emergent BioSolutions Stands With Analysts ↗

March 04, 2025

Via Benzinga

The Analyst Verdict: Emergent BioSolutions In The Eyes Of 4 Experts ↗

January 21, 2025

Via Benzinga

Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products

March 18, 2025

From Emergent BioSolutions

Via GlobeNewswire

Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs

March 13, 2025

From Emergent BioSolutions

Via GlobeNewswire

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

March 12, 2025

From Emergent BioSolutions

Via GlobeNewswire

Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International

March 10, 2025

From Emergent BioSolutions

Via GlobeNewswire

Stocks Drop As Trade War Escalates: What's Driving Markets Tuesday? ↗

March 04, 2025

U.S. stocks plunged Tuesday as President Donald Trump‘s tariffs on key trade partners came into effect, prompting retaliatory measures and intensifying global trade tensions.

Via Benzinga

Topics World Trade

Emergent BioSolutions Stock Sinks As Q4 Revenue Plunges 30%, But Retail Clings To Profit Swing ↗

March 04, 2025

For the first quarter, Emergent forecasted revenue in the range of $200 million to $240 million, lower than an analyst estimate of $279 million.

Via Stocktwits

Emergent BioSolutions (EBS) Q4 2024 Earnings Call Transcript ↗

March 04, 2025

EBS earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

Get insights into the top gainers and losers of Monday's after-hours session. ↗

March 03, 2025

Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics.

Via Chartmill

Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results

March 03, 2025

From Emergent BioSolutions

Via GlobeNewswire

Tesla Rebounds While Tariffs Weigh On Manufacturing: What's Driving Markets Monday? ↗

March 03, 2025

Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%,...

Via Benzinga

Earnings Scheduled For March 3, 2025 ↗

March 03, 2025

Via Benzinga

Nvidia, Tesla Lead Tech Stock Rebound: What's Driving Markets Friday? ↗

February 28, 2025

Stocks recovered on Friday, with all three major indexes in the green, as the tech sector bounced back from Thursday's losses with NVIDIA Corp. (NASDAQ:NVDA) up 1.37% and Tesla, Inc. (NASDAQ:TSLA)

Via Benzinga

Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

February 18, 2025

Separately, Company leaders will attend and present at J.P. Morgan’s 2025 Leveraged Finance Conference on February 24, 2025

From Emergent BioSolutions

Via GlobeNewswire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

February 12, 2025

Via Benzinga

Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans

February 07, 2025

From Emergent BioSolutions

Via GlobeNewswire

Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)

January 16, 2025

From Emergent BioSolutions

Via GlobeNewswire

Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals

January 14, 2025

From Emergent BioSolutions

Via GlobeNewswire

Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola

January 13, 2025

From Emergent BioSolutions

Via GlobeNewswire

Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

January 08, 2025

From Emergent BioSolutions

Via GlobeNewswire

Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)

January 08, 2025

From Emergent BioSolutions

Via GlobeNewswire

Why Emergent BioSolutions Stock Blasted Higher Today ↗

December 30, 2024

Via The Motley Fool

Nasdaq Down Over 100 Points; US Pending Home Sales Increase In November ↗

December 30, 2024

Via Benzinga

Crude Oil Gains 1%; Chicago PMI Falls In December ↗

December 30, 2024

Via Benzinga

Cytek Biosciences, Emergent BioSolutions, Radiopharm Theranostics And Other Big Stocks Moving Higher On Monday ↗

December 30, 2024

Via Benzinga

This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

December 30, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.